Douglas JA - Search Results

1

Cognitive function of children with cystic fibrosis: deleterious effect of early malnutrition.

Koscik RL, Farrell PM, Kosorok MR, Zaremba KM, Laxova A, Lai HC, Douglas JA, Rock MJ, Splaingard ML. Koscik RL, et al. Among authors: douglas ja. Pediatrics. 2004 Jun;113(6):1549-58. doi: 10.1542/peds.113.6.1549. Pediatrics. 2004. PMID: 15173473 Clinical Trial.

2

Recovery of birth weight z score within 2 years of diagnosis is positively associated with pulmonary status at 6 years of age in children with cystic fibrosis.

Lai HJ, Shoff SM, Farrell PM; Wisconsin Cystic Fibrosis Neonatal Screening Group. Lai HJ, et al. Pediatrics. 2009 Feb;123(2):714-22. doi: 10.1542/peds.2007-3089. Pediatrics. 2009. PMID: 19171643 Free PMC article.

3

Quality of life of children with cystic fibrosis.

Koscik RL, Douglas JA, Zaremba K, Rock MJ, Splaingard ML, Laxova A, Farrell PM. Koscik RL, et al. Among authors: douglas ja. J Pediatr. 2005 Sep;147(3 Suppl):S64-8. doi: 10.1016/j.jpeds.2005.09.001. J Pediatr. 2005. PMID: 16202786

4

Preventing early, prolonged vitamin E deficiency: an opportunity for better cognitive outcomes via early diagnosis through neonatal screening.

Koscik RL, Lai HJ, Laxova A, Zaremba KM, Kosorok MR, Douglas JA, Rock MJ, Splaingard ML, Farrell PM. Koscik RL, et al. Among authors: douglas ja. J Pediatr. 2005 Sep;147(3 Suppl):S51-6. doi: 10.1016/j.jpeds.2005.08.003. J Pediatr. 2005. PMID: 16202783

5

Assessing the quality of life in children with cystic fibrosis.

Kotwicki RJ, Condra L, Vermeulen L, Wolf T, Douglas J, Farrell PM. Kotwicki RJ, et al. WMJ. 2001;100(5):50-4. WMJ. 2001. PMID: 11579801

6

Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma.

Huie M, Oettel K, Van Ummersen L, Kim KM, Zhang Y, Staab MJ, Horvath D, Marnocha R, Douglas J, Drezen A, Alberti D, Wilding G. Huie M, et al. Invest New Drugs. 2006 May;24(3):255-60. doi: 10.1007/s10637-005-3903-z. Invest New Drugs. 2006. PMID: 16205854 Clinical Trial.

7

Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test.

Hutson PR, Oettel K, Douglas J, Ritter M, Messing E, Staab MJ, Alberti D, Horvath D, Wilding G. Hutson PR, et al. Cancer Chemother Pharmacol. 2008 Aug;62(3):373-7. doi: 10.1007/s00280-007-0613-6. Epub 2007 Oct 9. Cancer Chemother Pharmacol. 2008. PMID: 17922273 Clinical Trial.

8

Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants.

Carbone PP, Pirsch JD, Thomas JP, Douglas JA, Verma AK, Larson PO, Snow S, Tutsch KD, Pauk D. Carbone PP, et al. Among authors: douglas ja. Cancer Epidemiol Biomarkers Prev. 2001 Jun;10(6):657-61. Cancer Epidemiol Biomarkers Prev. 2001. PMID: 11401916 Clinical Trial.

9

Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.

Carbone PP, Douglas JA, Larson PO, Verma AK, Blair IA, Pomplun M, Tutsch KD. Carbone PP, et al. Among authors: douglas ja. Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):907-12. Cancer Epidemiol Biomarkers Prev. 1998. PMID: 9796636 Clinical Trial.

10

Item response models for longitudinal quality of life data in clinical trials.

Douglas JA. Douglas JA. Stat Med. 1999 Nov 15;18(21):2917-31. doi: 10.1002/(sici)1097-0258(19991115)18:21<2917::aid-sim204>3.0.co;2-n. Stat Med. 1999. PMID: 10523750

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

133 results

Search Page

Filters